NICE Multiple Technology Appraisal Guidance No 210
Clopidogrel and modified-release dipyridamole for the
prevention of occlusive vascular events
Review of Technology Appraisal No. 90
The following NICE appraisal was published on the
15th December 2010:
NHSScotland should note that:
No important differences were identified for
this NICE appraisal and NHS Quality Improvement Scotland advises
that the recommendations are as valid for Scotland as for England
and Wales.
The recommendations replace the recommendations
in TA 90 relating to the use of clopidogrel and modified-release
dipyridamol in this indication.
The Scottish Medicines Consortium (SMC) has not
issued guidance to NHSScotland on the use of these
medicines in this indication.
NHSScotland should take account of the NICE
appraisal and this NHS Quality Improvement Scotland email in its
planning, funding and provision of services to ensure that
recommended drugs or treatments are made available to meet clinical
need.
Copies of the NICE appraisal can be downloaded
from http://www.nice.org.uk.
Also on the website are tools (a costing report and template)
that NICE has developed to help organisations implement this
guidance. NICE MTA costing templates now include the NHSScotland
boards. However, please note that the care pathway described in the
costing tool may not completely reflect practice in
NHSScotland.
Finally, an easy to read summary of the
appraisal, called "understanding NICE guidance" is published on the
NICE website to provide information for patients and the
public.
NHS Quality Improvement Scotland advice
represents the evidence-based view of NHS Quality Improvement
Scotland.
This advice does not override or replace the
individual responsibility of health professionals to make
appropriate decisions in the circumstances of their individual
patients, in consultation with the patient and/or guardian or
carer.
7. No other publications on the NICE appraisal
will be issued by NHS Quality Improvement Scotland.
Published Date: 15 December 2010
